{'fraction_non_alphanumeric': 0.030821917808219176, 'fraction_numerical': 0.026151930261519303, 'mean_word_length': 5.0508474576271185, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
AB1326 Nicotinamide phosphoribosyltransferase may be new factors contributing to osteoarthritis

Background Obesity is a condition that prolongs chronic inflammation and promotes synthesis and secretion of pro-inflammatory factors by adipose tissue including adipokines1 and can be one of the significant factors in the progression of osteoarthritis (OA).2 Nowadays many studies have shown that level nicotinamide phosphoribosyltransferase (Nampt) increases in obesity and can also affect the inflammation in local tissues and together with other adipokines influences the development of OA.3 Objectives To study the effect of weight loss over 5 kg on the clinical manifestations of OA, indicators of water, lipid metabolism and Nampt serum levels in patients with OA. Methods We observed 110 people: 80 patients with OA and 30 healthy individuals in the control group with body mass index (BMI) of 25 to 35 kg/m 2, aged 18 to 79 years participated in the study. Nampt level in serum was determined by indirect solid phase ELISA using a commercial test systems (RaiBiotech, cat № EIA – VIS −1). Results As overweight patients were recruited in the study, hypocaloric diet low in animal fats and physiotherapy has been recommended to all participants. The first group consisted of patients who were able to reduce body weight by 5 kg and more (18 pers.), the second group – patients with weight reduction of less than 5 kg and patients without any weight loss (62 pers.). Nampt concentration were evaluated in these patients I groups 4,33±0,39 before treatment to 2,40±0,23 ng/ml (t=5,85, p<0,001). In analysing the parameters before and after treatment, it should be noted that we observed significant decrease in the severity of the clinical manifestations of OA, visfatin level, CRP, and glucose levels and lipid profile in the 1st group of patients. These data proves that obesity may be an important risk factor for OA progression. As a result, weight loss results in decreasing metabolic disorder severity. In the second group of patients we have seen a decrease in all the parameters, but a significant difference has been observed only in the level of CRP, level of pain at rest and during walking according to VAS scale and total index on the WOMAC. Conclusions As a result of our study patients with OA with weight loss of more than 5 kg had more obvious pain relief than patients with the original weight. At the same time a significant improvement has been seen in carbohydrate and lipid metabolism. These findings suggest that there is a possible role of Nampt in the pathogenesis of OA. References [1] Akhverdyan Y, Zavodovsky B, Seewordova L, et al. Adipokines as new laboratory markers in osteoarthritis. Ann Rheum Dis 2013;72(Suppls3):702. [2] Polyakova Y, Seewordova L, Akhverdyan Y. et al. Some pathophysiological aspects of pain syndrome in osteoarthritis. Osteoporosis International 2017;28(Suppl 1:154. [3] . Sivordova LE, Simakova ES, Polyakova JV, et al. Overweight and high level of nicotinamide phosphoribosyltransferase as factors contributing to osteoarthritis progression and metabolic syndrome development. Bulgarian medicine2016;Tom VI, 1:11–13. Disclosure of Interest None declared